Rationale for frequency and dose of administration in gestrinone therapy for pelvic endometriosis in the experimental model of rabbit uterus

T Tamaya; Teruhiko Tamaya; K Wada; Keisuke Wada; A Imai; Atsushi Imai; H Mori; Hidehiro Mori; Hideaki Ban; H Ban

doi:10.1016/0306-3623(91)90014-w

Rationale for frequency and dose of administration in gestrinone therapy for pelvic endometriosis in the experimental model of rabbit uterus

T Tamaya, Teruhiko Tamaya, K Wada, Keisuke Wada, A Imai, Atsushi Imai, H Mori, Hidehiro Mori, Hideaki Ban, H Ban

General pharmacology · 1991 · vol. 22(3) , pp. 505–510 · doi:10.1016/0306-3623(91)90014-w · PMID:1869024 · W2041173504

article OA: closed CC0 ⤵ 2 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated the optimal frequency and dosage of gestrinone administration for treating pelvic endometriosis in a rabbit uterine model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gestrinone Animals Cytosol Cytosol Cytosol DNA DNA Endometriosis Estrogens Estrogens Female Gestrinone In Vitro Techniques Organ Size Organ Size Potassium Chloride Potassium Chloride Progesterone Progesterone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (2)

References (11)

Gestrinone (R2323) Binding to Steroid Receptors in Human Uterine Endometrial Cytosol via openalex
Studies on type II estrogen binding sites : Relation between the effects on these sites of estrogen priming and the antiestrogen effects by danazol and progesterone. via openalex
Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesterone via openalex
Treatment of Pelvic Endometriosis with Gestrinone ‐Report on 9 Cases ‐ via openalex
W2078154328 via openalex
W2089257431 via openalex
W94025424 via openalex
W4299415996 via openalex
W1906197854 via openalex
W1983649348 via openalex
W2037595387 via openalex

Cited by (2)

Source provenance

europepmc: last seen: 2026-06-24T06:10:11.469335+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-05-13T22:12:05.481982+00:00

License: CC0 · commercial use OK

[1] Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesterone 1982

[2] Gestrinone (R2323) Binding to Steroid Receptors in Human Uterine Endometrial Cytosol 1986

[3] Studies on type II estrogen binding sites : Relation between the effects on these sites of estrogen priming and the antiestrogen effects by danazol and progesterone. 1986

[4] Treatment of Pelvic Endometriosis with Gestrinone ‐Report on 9 Cases ‐ 1985